ACET Company Profile and Key Details

Adicet Bio, Inc. generated EPS of -$20.22 over the past year. Five-year average earnings growth is 36.74%. Wall Street analysts project EPS growth of -9.41% annually over the next five years. The latest quarter delivered EPS of -$1.88. The next quarter is forecast at -$2.91. Next year's EPS is expected at $18.41. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $128.00 to $7.00. The high target offers 1305.05% upside. The low target suggests -23.16% downside. The mean target is $47.00. This offers 415.92% upside. Adicet Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 13, 2026, missed forecasts by -38.88%. The prior quarter beat by -8.98%. Over the last six quarters, Apple has recorded several small beats. These include -13.51% in March 06, 2025.

Adicet Bio, Inc. has 9.35 million shares outstanding. The public float is 7.43 million shares, elevated short interest at 4.11% of float. This equals 383.17 thousand shares. The short ratio is 4.21 days. Institutional investors hold 64.02% of the float. Insiders own 1.08%. SILVERSTEIN JONATHAN holds 4.83 million shares, Sinclair Andrew has 2.14 million shares and PureTech Health LLC has 2.12 million shares. Over the past six months, insider transactions show net buying. They sold 42.82 thousand shares across 2 transactions.

Adicet Bio, Inc. trades at a P/E ratio of -0.61, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.7 suggesting the stock is closer to book value. The P/FCF stands at -0.93, also above market averages.

Adicet Bio, Inc. last paid a dividend of 0.15 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.51. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Adicet Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.43%, with price expected at $8.16 by August 13, 2026, within a range of $7.84 to $8.51 3-Month Outlook: Projected fall of -55.87%, reaching $4.02 by October 28, 2026, with a range of $3.82 to $4.27. 1-Year Outlook: Projected gain of 190.23%, with price at $26.44 by July 30, 2027, within a range of $26.26 to $26.59.

Adicet Bio, Inc. (NASDAQ:ACET) shares are flat -6.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Adicet Bio, Inc. trading at a premium to the broader market with a P/E of -0.61. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $26.57, suggesting 191.66% upside. Our AI forecast model points to short-term weakness (-10.43% over two weeks), a medium-term fall (-55.87% over three months), and a longer-term gain (190.23% over one year), with expected trading ranges indicating moderate volatility.

Adicet Bio, Inc. (NASDAQ:ACET) closed at $9.11 USD, gaining $0.05 (0.55%) from the previous close of $9.06. The stock is currently mid-range between its 52-week high and low $6.01 and $17.44. With a market capitalization of about $85.16 million, Adicet Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.59). Key stats such as the average daily volume over the past year has been around 96.71 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Adicet Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chen Schor, the company employs approximately 102 people and listed since January 26, 2018. Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases.